Seminars in Nephrology
Volume 24, Issue 4 , Pages 354-365 , July 2004

Nitric oxide, oxidative stress, and progression of chronic renal failure

  • Paul S Modlinger

      Affiliations

    • Division of Nephrology and Hypertension and the Cardiovascular-Kidney Institute, Georgetown University, Washington, DC, USA
    • ,
  • Christopher S Wilcox

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Christopher S. Wilcox, MD, PhD, Division of Nephrology and Hypertension, Georgetown University Medical Center, 3800 Reservoir Rd, NW, PHC F6003, Washington, DC 20007 USA
    • Division of Nephrology and Hypertension and the Cardiovascular-Kidney Institute, Georgetown University, Washington, DC, USA
    • ,
  • Shakil Aslam

      Affiliations

    • Division of Nephrology and Hypertension and the Cardiovascular-Kidney Institute, Georgetown University, Washington, DC, USA

References 

  1. Liaudet L, Soriano FG, Szabo C. Biology of nitric oxide signaling. Crit Care Med. 2000;28(suppl):N37–N52
  2. Murphy MP. Nitric oxide and cell death. Biochim Biophys Acta. 1999;1411:401–414
  3. Quaschning T, Krane V, Metzger T, et al.  Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis. 2001;38(suppl):S14–S19
  4. Becker BN, Himmelfarb J, Henrich WL, et al.  Reassessing the cardiac risk profile in chronic hemodialysis patients (A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors). J Am Soc Nephrol. 1997;8:475–486
  5. Zalba G, San Jose G, Moreno MU, et al.  Oxidative stress in arterial hypertension (Role of NAD(P)H oxidase). Hypertension. 2001;38:1395–1399
  6. Kitiyakara C, Gonin J, Massy Z, et al.  Non-traditional cardiovascular disease risk factors in end-stage renal disease (Oxidative stress and hyperhomocysteinemia). Curr Opin Nephrol Hypertens. 2001;9:477–487
  7. Mohaupt MG, Elzie JL, Ahn KY, et al.  Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int. 1994;46:653–665
  8. Ujiie K, Yuen J, Hogarth L, et al.  Localization and regulation of endothelial NO synthase mRNA expression in rat kidney. Am J Physiol. 1994;267:F296–F302
  9. Wilcox CS, Welch WJ, Murad F, et al.  Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci U S A. 1992;89:11993–11997
  10. Tojo A, Gross SS, Zhang L, et al.  Immunocytochemical localization of distinct isoforms of nitric oxide synthase in the juxtaglomerular apparatus of normal rat kidney. J Am Soc Nephrol. 1994;4:1438–1447
  11. Welch WJ, Tojo A, Lee JU, et al.  Nitric oxide synthase in the JGA of the SHR (Expression and role in tubuloglomerular feedback). Am J Physiol. 1999;277:F130–F138
  12. Ahn KY, Mohaupt MG, Madsen KM, et al.  In situ hybridization localization of mRNA encoding inducible nitric oxide synthase in rat kidney. Am J Physiol. 1994;267:F748–F757
  13. Majid DSA, Navar LG. Nitric oxide in the control of renal hemodynamics and excretory function. Am J Hypertens. 2001;14:S74–S81
  14. Wilcox CS. L-arginine-NO pathway. In:  Seldin DW,  Giebisch G editor. The Kidney (Physiology and Pathophysiology). New York: Raven Press; 2000;p. 849–871
  15. Ito S. Nitric oxide in the kidney. Curr Opin Nephrol Hypertens. 1995;4:28–30
  16. Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol. 1993;264:F212–F215
  17. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278–281
  18. Welch WJ, Wilcox CS. What is brain nitric oxide synthase doing in the kidney?. Curr Opin Nephrol Hypertens. 2002;11:109–115
  19. Bramm B, Koomans HA. Nitric oxide antagonizes the actions of angiotensin II to enhance tubuloglomerular feedback responsiveness. Kidney Int. 1995;48:1406–1411
  20. Welch WJ, Wilcox CS. Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure (Effects of salt intake). J Clin Invest. 1997;100:2235–2242
  21. Gschwend S, Buikema H, Navis G, et al.  Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol. 2002;13:2909–2915
  22. Ortiz PA, Garvin JL. Superoxide stimulates NaCl absorption by the thick ascending limb. Am J Physiol. 2002;283:F957–F962
  23. Tian N, Gannon AW, Khalil RA, et al.  Mechanisms of salt-sensitive hypertension (Role of renal medullary inducible nitric oxide synthase). Am J Physiol. 2003;284:R372–R379
  24. Majid DSA, Said KE, Omoro SA, et al.  Nitric oxide dependency of arterial pressure-induced changes in renal interstitial hydrostatic pressure in dogs. Circ Res. 2001;88:347–351
  25. Wang T. Role of iNOS and eNOS in modulating proximal tubule transport and acid-base balance. Am J Physiol. 2002;283:F658–F662
  26. Wu G, Morris SM. Arginine metabolism (Nitric oxide and beyond). Biochem J. 1998;336:1–17
  27. Bouby N, Hassler C, Parvy P, et al.  Renal synthesis of arginine in chronic renal failure (In vivo and in vitro studies in rats with 5/6 nephrectomy). Kidney Int. 1993;44:676–683
  28. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis. 2001;38(suppl 1):S74–S79
  29. Vallance P, Leone A, Calver A, et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575
  30. Schmidt RJ, Yokota S, Tracy TS, et al.  Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol. 1999;276:F794–F797
  31. Closs EI. Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens. 2002;11:99–107
  32. Tojo A, Kimoto M, Wilcox CS. Renal expression of constitutive NOS and DDAH (Separate effects of salt intake and angiotensin). Kidney Int. 2000;58:2075–2083
  33. Deng X, Welch WJ, Wilcox CS. Renal vasodilation with L-arginine (Effects of dietary salt). Hypertension. 1995;26:256–262
  34. Kitiyakara C, Chabrashvili T, Jose P, et al.  Effects of dietary salt intake on plasma arginine. Am J Physiol. 2001;280:R1069–R1075
  35. Aiello S, Noris M, Todeschini M, et al.  Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int. 1997;52:171–181
  36. Aiello S, Noris M, Remuzzi G. Nitric oxide/L-arginine in uremia. Miner Electrolyte Metab. 1999;25:384–390
  37. Vaziri ND, Ni Z, Wang XQ, et al.  Downregulation of nitric oxide synthase in chronic renal insufficiency (Role of excess PTH). Am J Physiol. 1998;274:F642–F649
  38. Panza JA, Garcia CE, Kilcoyne CM, et al.  Impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation. 1995;91:1732–1738
  39. Welch WJ, Wilcox CS. AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int. 2001;59:1257–1263
  40. Welch WJ, Tojo A, Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol. 2000;278:F769–F776
  41. Blum M, Yachnin T, Wollman Y, et al.  Low nitric oxide production in patients with chronic renal failure. Nephron. 1998;79:265–268
  42. Schmidt RJ, Domico J, Samsell LS, et al.  Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis. 1999;34:228–234
  43. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000;58:1261–1266
  44. Xiao S, Wagner L, Schmidt RJ, et al.  Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 2001;59:1466–1472
  45. Xiao S, Wagner L, Mahaney J, et al.  Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol. 2001;280:F989–F995
  46. Wever R, Boer P, Hijmering M, et al.  Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 1999;19:1168–1172
  47. Forte P, Copland M, Smith LM, et al.  Basal nitric oxide synthesis in essential hypertension. Lancet. 1997;349:837–842
  48. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2000;11:1371–1376
  49. Cross JM, Donald AE, Kharbanda R, et al.  Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int. 2001;60:2318–2323
  50. Wilcox CS. Reactive oxygen species (Role in blood pressure and kidney function). Curr Hypertens Rep. 2002;4:160–166
  51. Gorlach A, Brandes RP, Nguyen K, et al.  A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26–32
  52. Lassegue B, Sorescu D, Szocs K, et al.  Novel gp91phox homologues in vascular smooth muscle cells (Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways). Circ Res. 2001;88:888–894
  53. Zou AP, Li N, Cowley AW. Production and actions of superoxide in the renal medulla. Hypertension. 2001;37:547–553
  54. Makino A, Skelton MM, Zou AP, et al.  Increased renal medullary oxidative stress produces hypertension. Hypertension. 2002;39:667–672
  55. Li N, Yi FX, Spurrier JL, et al.  Production of superoxide through NADH oxidase in thick ascending limb of Henle’s loop in rat kidney. Am J Physiol. 2002;282:F1111–F1119
  56. Chabrashvili T, Tojo A, Onozato ML, et al.  Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39:269–274
  57. Zalba G, Beaumont FJ, San Jose G, et al.  Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension. 2000;35:1055–1061
  58. Kawada N, Imai E, Karber A, et al.  A mouse model of angiotensin II slow pressor response (Role of oxidative stress). J Am Soc Nephrol. 2002;13:2860–2868
  59. Cifuentes ME, Rey FE, Carretero OA, et al.  Upregulation of p67phox and gp91phox in aortas from angiotensin II-infused mice. Am J Physiol. 2000;279:H2234–H2240
  60. Chabrashvili T, Kitiyakara C, Blau J, et al.  Effects of Ang II type 1 and type 2 receptors on oxidative stress and renal NADPH oxidase and SODs expression. Am J Physiol. 2003;285:R117–R124
  61. Lenda DM, Boegehold MA. Effect of a high-salt diet on oxidant enzyme activity in skeletal muscle microcirculation. Am J Physiol. 2002;282:H395–H402
  62. Beswick RA, Dorrance AM, Leite R, et al.  NADH/NADPH oxidase and enchanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107–1111
  63. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res. 2001;89:753–762
  64. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radical in the renal microvasculature. Am J Physiol. 2002;282:R335–R342
  65. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic (Role of nitric oxide). Hypertension. 1998;32:59–64
  66. Majid DSA, Nishiyama A. Nitric oxide blockade enhances renal responses to superoxide dismutase inhibition in dogs. Hypertension. 2002;39:293–297
  67. Zhou XJ, Vaziri ND, Wang XQ, et al.  Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase. J Pharmacol Exp Ther. 2002;300:762–767
  68. Vaziri ND, Wang XQ, Oveisi F, et al.  Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000;36:142–146
  69. Ganafa AA, Socci RR, Eatman D, et al.  Acute inhibition of glutathione biosynthesis alters endothelial function and blood pressure in rats. Eur J Pharmacol. 2002;454:217–223
  70. Vaziri ND, Ni Z, Oveisi F, et al.  Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension. 2002;39:135–141
  71. Vaziri ND, Dicus M, Ho ND, et al.  Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003;63:179–185
  72. Hasdan G, Benchetrit S, Rashid G, et al.  Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int. 2002;61:586–590
  73. Gaertner SA, Janssen U, Ostendorf T, et al.  Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2002;13:2930–2937
  74. Annuk M, Lind L, Linde T, et al.  Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant. 2001;16:302–306
  75. van Guldener C, Janssen MJ, Lambert J, et al.  Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant. 1998;13:1782–1786
  76. Kari JA, Donald AE, Vallance DT, et al.  Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997;52:468–472
  77. Annuk M, Zilmer M, Lind L, et al.  Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12:2747
  78. Handelman GJ, Walter MF, Adhikarla R, et al.  Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001;59:1960–1966
  79. Clermont G, Lecour S, Lahet J, et al.  Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients (A possible explanation for the increased cardiovascular risk in these patients). Cardiovasc Res. 2000;47:618–623
  80. Ikizler TA, Morrow JD, Roberts LJ, et al: Plasma F2- isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58:190–197, 20032
  81. Mimic-Oka J, Simic T, Djukanovic L, et al.  Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999;51:233–241
  82. Himmelfarb J, Stenvinkel P, Ikizler TA, et al.  The elephant in uremia (Oxidant stress as a unifying concept of cardiovascular disease in uremia). Kidney Int. 2002;62:1524–1538
  83. Erdogan C, Unlucerci Y, Turkmen A, et al.  The evaluation of oxidative stress in patients with chronic renal failure. Clin Chim Acta. 2002;322:157–161
  84. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38(suppl 1):S100–S106
  85. Raj DSC, Choudhury D, Welbourne TC, et al.  Advanced glycation end products (A nephrologist’s perspective). Am J Kidney Dis. 2000;35:365–380
  86. Attia DM, Vergagen AM, Stroes ES, et al.  Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol. 2001;12:2585–2593
  87. Stulak JM, Lerman A, Porcel MR, et al.  Renal vascular function in hypercholesterolemia is preserved by chronic antioxidant supplementation. J Am Soc Nephrol. 2001;12:1882–1891
  88. Ganafa AA, Socci RR, Eatman D, et al.  Effect of palm oil on oxidative stress-induced hypertension in Sprague-Dawley rats. Am J Hypertens. 2002;15:725–731
  89. De Caterina R, Cipollone F, Filard FP, et al.  Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects (No further effect of vitamin E). Circulation. 2002;106:2543–2549
  90. Waddington S, Cook HT, Reaveley D, et al.  L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney Int. 1996;49:1090–1096
  91. Ashab I, Peer G, Blum M, et al.  Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995;47:1515–1521
  92. Katoh T, Takahashi K, Klahr S, et al.  Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol. 1994;4:1690–1694
  93. Reyes AA, Karl IE, Kissane J, et al.  L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol. 1993;4:1039–1045
  94. Bennett-Richards KJ, Kattenhorn M, Donald AE, et al.  Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int. 2002;62:1372–1378
  95. Deng G, Vaziri ND, Jabbari B, et al.  Increased tyrosine nitration of the brain in chronic renal insufficiency (Reversal by antioxidant therapy and angiotensin-converting enzyme inhibition). J Am Soc Nephrol. 2001;12:1892–1899
  96. Onozato ML, Tojo A, Goto A, et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy (Effects of ACEI or ARB). Kidney Int. 2002;61:186–194
  97. de Gasparo M, Hess P, Clozel M, et al.  Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002;40:789–800
  98. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialysis on oxidant stress. Kidney Int. 2003;63:353–359
  99. Tarng DC, Huang TP, Liu TY, et al.  Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 2000;58:790–799
  100. Tarng DC, Wei YH, Huang TP, et al.  Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999;55:2477–2486
  101. Mune M, Yukawa S, Kishino M, et al.  Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int. 1999;56:S126–S129
  102. Tsuruoka S, Kawaguchi AT, Nishiki K, et al.  Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis. 2002;39:127–133
  103. Clermont G, Lecour S, Cabanne JF, et al.  Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients. Free Radic Biol Med. 2001;31:233–241
  104. Arosio E, De Marchi S, Zannoni M, et al.  Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease (A randomized, double-blind, placebo-controlled trial). Mayo Clin Proc. 2002;77:754–759
  105. Boaz M, Smetana S, Weinstein T, et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) (Randomised placebo-controlled trial). Lancet. 2000;356:1213–1218
  106. Robert CK, Vaziri ND, Barnard RJ. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation. 2002;106:2530–2532

☆ Supported by the National Institute for Diabetes and Digestive and Kidney Diseases (grants DK-36079 and DK-49870) and the National Heart, Lung & Blood Institute (grant HL HL68686-01), and by funds from the George E. Schreiner Chair of Nephrology (C.S.W.); and by a National Institutes of Health/National Institute for Diabetes and Digestive and Kidney Diseases Nephrology and Hypertension Training grant (DK-59274) (P.M.).

PII: S0270-9295(04)00055-5

doi: 10.1016/j.semnephrol.2004.04.007

Seminars in Nephrology
Volume 24, Issue 4 , Pages 354-365 , July 2004

Article Tools

* Image Usage & Resolution